Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193271 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00193271 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 30 participants.
The verdict
NCT00193271, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.
Interventions
- DRUG Docetaxel
- DRUG Estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193271
The ClinicalTrials.gov registry entry for NCT00193271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00193271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193271 about?
NCT00193271 is a clinical study titled "Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer". This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.
What is the current status of trial NCT00193271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-08. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00193271?
The interventions under investigation include: Docetaxel (DRUG), Estramustine (DRUG).
Who is sponsoring clinical trial NCT00193271?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.